Heart Valve Repair Cuts Death and Hospitalization Risk by 60% in High-Risk Patients
A German trial found that a minimally invasive tricuspid valve repair cut the risk of death or heart failure hospitalization by roughly 60 percent over three years in high-risk patients, resolving a question that had lingered since earlier trials.
A large German trial has shown, for the first time, that a minimally invasive heart valve repair can meaningfully cut the risk of death or hospitalization in high-risk patients with a leaking tricuspid valve, resolving a question that has hung over the field for years.
Results from the trial, called TRIC-I-HF, were presented August 30, 2026, at the European Society of Cardiology Congress in Munich and published simultaneously in the New England Journal of Medicine. The study was led by Professor Jorg Hausleiter and Professor Thomas Stocker of Ludwig-Maximilians-University in Munich, across 29 high-volume heart valve centers in Germany.
A common problem with few good options
The tricuspid valve controls blood flow on the right side of the heart, and when it fails to close properly, blood leaks backward, a condition called tricuspid regurgitation. Severe cases are strongly linked to poorer survival and repeated hospital admissions, but medical treatment options have historically been limited, and open-heart surgery is often too risky for the older, frailer patients who tend to develop the condition. That combination has left many patients with few real alternatives beyond medication aimed at managing symptoms.
In recent years, a catheter-based technique called transcatheter edge-to-edge repair, which clips the valve's leaflets together through a vein rather than open surgery, has offered a less invasive option. But whether it actually helped patients live longer or stay out of the hospital, rather than just easing symptoms, had not been convincingly shown.
What the new trial found
TRIC-I-HF enrolled 360 patients with severe tricuspid regurgitation and a history of heart failure hospitalization, cardiorenal syndrome, or cardiohepatic syndrome, a population specifically chosen because they were considered high-risk. Average age was just over 80, and more than half were women. Researchers randomly assigned 237 patients to receive transcatheter repair alongside medical therapy, and 123 to medical therapy alone; 98 percent of the intervention group received the catheter-based repair.
At three years, 52.4 percent of patients who received the repair were alive and free of a heart failure hospitalization, compared with just 21.0 percent of those on medical therapy alone, a difference researchers described using a hazard ratio of 0.40, meaning the risk of death or hospitalization was cut by roughly 60 percent in the repair group. A separate one-year analysis using a statistical method called a win ratio, which weighs multiple outcomes together, also favored the procedure by more than two to one.
Why this result stands out
The significance of TRIC-I-HF becomes clearer against the backdrop of TRILUMINATE, the earlier pivotal trial that led to approval of a leading tricuspid repair device. That trial found the procedure meaningfully improved patients' quality of life and walking distance, but it explicitly did not reduce mortality or hospitalization at one year: 90.6 percent of device patients were free of death or valve surgery, versus 89.9 percent on medical therapy, a difference with no statistical significance. Stocker's own framing of the open question, that "their effect on heart failure hospitalizations and mortality remained unclear," reflects exactly that gap in the evidence.
TRIC-I-HF is the first trial to report a large, statistically robust benefit on those harder outcomes, in a population selected specifically for elevated risk. That distinction, a hard clinical endpoint rather than a quality-of-life measure, is what is likely to shift how cardiologists think about offering the procedure to similar patients.
What comes next
The findings apply to a specific high-risk group and come from trial centers with substantial experience performing the procedure, so how the results translate to broader, more typical clinical settings will be an important next question. Longer-term follow-up beyond three years, and confirmation in other patient populations, will also help clarify how durable the benefit is.
For a condition that has offered patients little beyond symptom management, a therapy now shown to meaningfully extend time free of hospitalization and death is a significant step forward, and one that may open the door to some patients being offered the procedure earlier in the course of their disease.
